Business Description
N4 Pharma PLC
NAICS : 423430
ISIN : GB00BYW8QM32
Description
Financial Strength
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.89 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -2.06 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 23.1 | |||||
3-Year EPS without NRI Growth Rate | 20.6 | |||||
3-Year FCF Growth Rate | 20.6 | |||||
3-Year Book Growth Rate | -41.5 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 0.3 | |||||
9-Day RSI | 3.35 | |||||
14-Day RSI | 8.08 | |||||
6-1 Month Momentum % | -11.11 | |||||
12-1 Month Momentum % | -54.29 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 14.8 | |||||
Quick Ratio | 14.8 | |||||
Cash Ratio | 12.52 | |||||
Days Sales Outstanding | 21626.25 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -14.1 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -66800 | |||||
Net Margin % | -63450 | |||||
FCF Margin % | -60500 | |||||
ROE % | -81.68 | |||||
ROA % | -77.06 | |||||
ROIC % | -578.33 | |||||
ROC (Joel Greenblatt) % | -1009.57 | |||||
ROCE % | -84.81 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 1.38 | |||||
Price-to-Tangible-Book | 1.38 | |||||
EV-to-EBIT | -0.34 | |||||
EV-to-EBITDA | -0.34 | |||||
EV-to-Revenue | 225.5 | |||||
EV-to-FCF | -0.37 | |||||
Earnings Yield (Greenblatt) % | -294.12 | |||||
FCF Yield % | -81.87 | |||||
Forward Rate of Return (Yacktman) % | -1047.9 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
N4 Pharma PLC Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil £) | 0.002 | ||
EPS (TTM) (£) | -0.005 | ||
Beta | 0.73 | ||
Volatility % | 49.62 | ||
14-Day RSI | 8.08 | ||
14-Day ATR (£) | 0.000223 | ||
20-Day SMA (£) | 0.0072 | ||
12-1 Month Momentum % | -54.29 | ||
52-Week Range (£) | 0.00486 - 0.0175 | ||
Shares Outstanding (Mil) | 268.78 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
N4 Pharma PLC Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
N4 Pharma PLC Stock Events
Event | Date | Price(£) | ||
---|---|---|---|---|
No Event Data |
N4 Pharma PLC Frequently Asked Questions
What is N4 Pharma PLC(AQSE:N4P.GB)'s stock price today?
When is next earnings date of N4 Pharma PLC(AQSE:N4P.GB)?
Does N4 Pharma PLC(AQSE:N4P.GB) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |